Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Elevated CA125: investigation & management, Gynaecology (1113)
Announcements and latest updates

Right Decision Service newsletter: October 2024

Welcome to the Right Decision Service (RDS) newsletter for October 2024.

1.Contingency arrangements for RDS outages

Development of the contingency solutions to maximise RDS resilience and minimise risk of future outages is in progress, aiming for completion by Christmas. As a reminder, these contingency arrangements  are:

  • Optimising mobile app build process
  • Mobile app always to be downloadable.
  • Serialising builds to mobile app; separate mobile app build from other editorial and end-user processes
  • Load balancing – provides failover (also enables separation of editorial processes from other processes to improve performance.)

 

In the meantime, a gentle reminder to encourage users to download essential clinical toolkits to their mobile devices so that there is an offline version always available.

 

2. New deployment with improvements.

A new scheduled deployment with minor improvements drawn from support tickets, externally funded projects, information related to outages, and feature requests will take place in early December. Key improvements planned are:

  • Deep-linking to individual toolkits within the RDS mobile app. Each toolkit will now have its own direct URL and QR code, both accessible from the app. These can be used to download the toolkit directly where users already have the RDS app installed. If the user does not yet have the RDS app installed, they will be taken to the app store to install the app and immediately afterwards the toolkit will automatically open and download. Note that this will go live a few days later than the improvements below due to the need to link up the mobile front end to the changes in the content management system.
  • Introducing an Announcement Header field to replace the hardcoded "Announcements and latest updates" text. This will enable users to see at a glance the focus of new announcements.
  • Automated daily emptying of the recycling bin (with a 30 day rolling grace period)  in the content management system. A bug preventing complete emptying of the recycling bin contributed to one of the outages earlier this year.
  • Supporting multiple passcodes (ticket 6079)
  • Expanding accordion section to show location of a search result rather than requiring user coming from a search result to manually open all sections and search again for the term.
  • Displaying first accordion section Content text as a snippet on the search results page as a fallback if default/main content is not provided
  • Displaying the context of each search result in the form of a link to the relevant parent tool/section. This will help users to choose which search result is most likely to be appropriate for their needs.
  • As part of release of the new national benzodiazepine quality prescribing guidance toolkit sponsored by Scottish Government Effective Prescribing and Therapeutics, a digital tool to support creation of benzodiazepine tapering/withdrawal schedules.

We are also seeking approval to use the NHS Scotland logo and title for the RDS app on the app stores to help with audience engagement and clarity around the provenance of RDS.

3. RDS Search, Browse and Archive/Version control enhancements

We are still hopeful that user acceptance testing for at least the Search and browse enhancements can take place before Christmas. Thank you for your patience and understanding in waiting for these improvements. Timescales have been pushed back by old app migration challenges, work to address outages, and most recently implementing the contingency arrangements.

4. Support tickets

We are aware that there continue to be some issues around a number of RDS support tickets, in part due to constraints around visibility for the RDS team of the tickets in the existing  support portal. We are investigating the potential to move to a new support ticket requesting system from early in the new year. We will organise the proposed webinar around support ticket processes once we have confirmed the way forward with the system.

Table formatting

There is a known issue with alterations in formatting of some RDS tables which seems to have arisen as a result of the 17 October deployment. Tactuum is working on a fix and on implementing additional regression testing to prevent this issue recurring.

5. New RDS toolkits

Recently launched toolkits include:

NHS Lothian Infectious Diseases

Scottish Health Technologies Group – Technology Assessment recommendations

NHS Tayside Anaesthetics and Critical Care projects – an innovative toolkit which uses PowerAutomate to manage review and response to proposals for improvement projects.

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

A number of toolkits are expected to go live before Christmas, including:

  • Focus on dementia
  • Highland Council Getting it Right for Every Child
  • Dumfries and Galloway Adult Support and Protection procedures
  • National Waiting Well toolkit
  • Fertility Scotland National Network
  • NHS Lothian postural care for care homes

6.Sign up to RDS Editors Teams channel

We have had a good response to the recent invitation to sign up to the new Teams channel for RDS editors. This provides a forum for editors to share learning, ideas and questions and we hope to hold regular webinars on topics of interest.  The RDS team is in the process of joining participants to the channel and we’d encourage all editors to take part, using the registration form – available in Providers section of the RDS Learning and Support area.

 

7. Evaluation projects

The RDS team has worked with colleagues in NHS Grampian and the Digital Health & Care Innovation Centre to evaluate the impact of the Prevent the progress of diabetes web and mobile app in a small-scale pilot project. This app provides access to local and national resources and services targeted at people with prediabetes, a history of gestational diabetes, or candidates for remission. After just 8 weeks of using the app, 94% of patients reported increased their knowledge and understanding of diabetes, and 88% said it had increased their confidence and motivation to make lifestyle changes, highlighting specific behaviour changes. The learning from this project is informing development of a service model based on tailored support for patient groups with, high, medium and low digital self-efficacy.

Please contact ann.wales3@nhs.scot if you would like to know more about this project.

  1. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 29th November 3-4 pm
  • Thursday 5 December 3.30 -4.30 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

The Right Decision Service:  the national decision support platform for Scotland’s health and care

Website: https://rightdecisions.scot.nhs.uk    Mobile app download:  Apple  Android

 

 

Elevated CA125: investigation & management, Gynaecology (1113)

Warning

Objectives

To provide guidance on how to investigate women where a raised CA125 is found

Audience

Healthcare providers in primary and secondary care in Great Glasgow and Clyde (GGC)

CA125 is considered to be the best available marker for epithelial ovarian cancer.  

The widely accepted normal range of CA125 in GGC is 0-35 IU/ml.

Clinical Specificity of CA125

CA125 may be elevated in many physiological and pathological conditions, with gynaecological and non-gynaecological causes.  These conditions are summarised in the table below.

Table: list of conditions causing a raised CA125

CA125 Testing Recommendations

Primary Care

NICE recommends CA125 testing in primary care in women presenting with  1 of these following symptoms on a persistent or frequent basis, particularly if ≥ 12 x per month.

  • Persistent abdominal distension (‘bloating’)
  • Early satiety +/- loss of appetite
  • Pelvic or abdominal pain
  • Increased urinary urgency +/- frequency
  • Unexplained weight loss
  • Unexplained fatigue
  • Unexplained change of bowel habit
  • New onset of symptoms suggestive of IBS if 50 years

If CA125 is elevated >35 IU/ml, arrange an Ultrasound of the Pelvis – ideally Transvaginal Scan within 2 weeks.

Additionally if physical examination in primary care suggests ascites and or a pelvic or abdominal mass (which is not obviously uterine fibroids) they should be referred urgently for review in gynaecology and referral should not be delayed whilst waiting for CA125 result. 

Secondary Care

Abnormal Ultrasound Scan or imaging findings – premenopausal women

The Royal College of Obstetricians and Gynaecologists (RCOG) advises that a CA125 level is not routinely needed for the diagnosis of a simple cysts in premenopausal women. 

If germ cell origin tumours are suspected following imaging (e.g. women < 40yrs), αFP, βHCG and LDH are recommended in addition to CA125.

Please see GGC guidelines for further details.

Abnormal Ultrasound Scan or imaging findings – postmenopausal women

A CA125 level should be measured in all postmenopausal women with a cystic lesion of 1cm or more.  This should be used in conjunction with the USS findings to calculate the Risk of Malignancy Index Score (RMI).  Please see GGC guidelines for further details.

Normal pelvic ultrasound scan or imaging & Raised CA125

If a CA125 has been measured prior to imaging, a normal ultrasound can exclude ovarian cancer with a high degree of confidence. 

Postmenopausal ovaries will appear smaller and more homogenous compared to those found in pre-menopausal women. It is therefore common not to visualize the ovaries on ultrasound in a postmenopausal woman.  For completeness an abdominal examination and bimanual examination may be undertaken to assess for potential non pelvic masses.

In the presence of a normal pelvic ultrasound scan or imaging, there is no clear evidence to repeat a CA125 measurement.  However, extrapolating from ovarian cyst data, a rapidly rising CA125 is more likely to be associated with malignancy, therefore consider a repeat CA125 after 8 weeks to assess trend.  If significantly rising, further imaging by urgent CT scan of abdomen and pelvis should be arranged. 

If no gynaecological cause identified, patient should be referred back to GP to assess for other clinical causes of symptoms and investigate or refer as appropriate.

CA125 Flowchart

Flowchart of the steps for elevated CA125 investigations

Editorial Information

Last reviewed: 14/11/2023

Next review date: 31/10/2027

Author(s): Dr Jenifer Sassarini, Consultant O&G; Dr Claire Higgins Consultant O&G.

Approved By: Gynaecology Clinical Governance Group

Document Id: 1113

References

Ovarian cancer: recognition and initial management. NICE Guideline CG122 April 2011, Last review 2017.

Suspected cancer: recognition and referral, NICE guideline [NG12] Published: June 2015 Last updated: December 2021

Howe T, Sokolovsky N, Sayasneh A, Omar K, Tahmasebi F. Raised CA125–what we actually know... The Obstetrician & Gynaecologist2021;23:21–7.

RCOG Green-top Guideline No. 62. Management of suspected ovarian masses in premenopausal women. Dec 2011.

RCOG Green-top Guideline No. 34. Ovarian cysts in postmenopausal women. July 2016.

ACOG Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses, Obstetrics & Gynecology: November 2016 - Volume 128 - Issue 5 - p e210-e226

ACOG COMMITTEE OPINION Number 716 , September (Reaffirmed 2019) Committee on Gynecologic Practice Society of Gynecologic Oncology. The Role of the Obstetrician–Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk